1 Title Page

2

3 Title: Monitoring transmission intensity of trachoma with serology: a multi-country study

4

5 **Authors:** Christine Tedijanto¹, Anthony W. Solomon², Diana L. Martin³, Scott D. Nash⁴, Jeremy

- 6 D. Keenan^{1,5}, Thomas M. Lietman^{1,5,6,7}, Patrick J. Lammie⁸, Kristen Aiemjoy⁹, Abdou Amza^{10,11},
- 7 Solomon Aragie¹², Ahmed M. Arzika¹³, E. Kelly Callahan⁴, Sydney Carolan¹, Adisu Abebe
- 8 Dawed¹⁴, E. Brook Goodhew³, Sarah Gwyn³, Jaouad Hammou¹⁵, Boubacar Kadri¹¹, Khumbo
- 9 Kalua¹⁶, Ramatou Maliki¹³, Beido Nassirou¹¹, Fikre Seife¹⁷, Zerihun Tadesse¹², Sheila K. West¹⁸,
- 10 Dionna M. Wittberg¹, Taye Zeru¹⁹, Benjamin F. Arnold^{1,5}*
- 11

12 Author affiliations:

- ¹ Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA, 94158
- ¹⁴ ² Department of Control of Neglected Tropical Diseases, WHO, Geneva, Switzerland
- ¹⁵ ³ Division of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, GA,
- 16 USA 30329
- 17 ⁴ The Carter Center, Atlanta, GA, USA, 30307
- ⁵ Department of Ophthalmology, University of California San Francisco, San Francisco, CA, USA, 94158
- ⁶ Institute for Global Health Sciences, University of California San Francisco, San Francisco, CA 94143
- ²⁰ ⁷ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA
- 21 **94143**
- ⁸ Neglected Tropical Diseases Support Center, Task Force for Global Health, Atlanta, GA, USA, 30030
- ⁹ Division of Epidemiology, Department of Public Health Sciences, University of California Davis School of
- 24 Medicine, Davis, CA, USA
- ¹⁰ Programme FSS/Université Abdou Moumouni de Niamey, Programme National de Santé Oculaire,
- 26 Niamey, Niger
- 27 ¹¹ Programme National de Lutte Contre la Cecité, Niamey, Niger.
- 28 ¹² The Carter Center Ethiopia, Addis Ababa, Ethiopia
- 29 ¹³ The Carter Center Niger, Niamey, Niger
- 30 ¹⁴ Amhara Regional Health Bureau, Bahir-Dar, Ethiopia
- ¹⁵ Service of Ocular and Otological Diseases, Epidemiology and Disease Control Directorate, Ministry of
- 32 Health, Morocco
- 33 ¹⁶ Blantyre Institute for Community Outreach, Malawi
- ¹⁷ Federal Ministry of Health, Addis Ababa, Ethiopia
- ¹⁸ Johns Hopkins School of Medicine, Ophthalmology Department, Baltimore, USA, 21287
- 36 ¹⁹ Amhara Public Health Institute, Bahir-Dar, Ethiopia
- 37
- 38 * Corresponding Author:
- 39 Benjamin F. Arnold, PhD
- 40 Associate Professor
- 41 F.I. Proctor Foundation
- 42 University of California, San Francisco
- 43 ben.arnold@ucsf.edu
- 44

45 Abstract

Trachoma, caused by ocular *Chlamydia trachomatis* infection, is targeted for global 46 47 elimination as a public health problem by 2030. To provide evidence for use of antibodies to monitor C. trachomatis transmission, we collated IgG responses to Pgp3 48 antigen, PCR positivity, and clinical observations from 19,811 children aged 1-9 years 49 in 14 populations. We demonstrate that age-seroprevalence curves consistently shift 50 along a gradient of transmission intensity: rising steeply in populations with high levels 51 of infection and active trachoma and becoming flat in populations near elimination. 52 Seroprevalence (range: 0-54%) and seroconversion rates (range: 0-15 per 100 person-53 years) correlate with PCR prevalence (r: 0.88, 95% CI: 0.77, 0.93). A seroprevalence 54 55 threshold of 13.5% (seroconversion rate 2.75 per 100 person-years) identifies clusters with any infection at high sensitivity (>90%) and moderate specificity (69-75%). Antibody 56 responses in young children provide a robust, generalizable approach to monitor 57 population progress toward and beyond trachoma elimination. 58 59

60 Introduction

Trachoma is the leading infectious cause of blindness and has been targeted for 61 62 elimination as a public health problem by 2030.¹ Caused by repeated infections with the bacterium Chlamydia trachomatis (Ct), trachoma has historically been monitored via 63 district-level estimates of clinical signs.² However, clinical signs may not align well with 64 transmission intensity, particularly after mass drug administration of azithromycin (MDA) 65 ^{3–5}, and are prone to measurement error, especially as cases become rare.^{6–8} As a 66 result, there has been growing interest in IgG antibody responses as an objective and 67 easy-to-collect biomarker to inform control programs. Based on examples from other 68 infectious diseases including malaria⁹ and SARS-CoV-2.¹⁰ use cases for trachoma 69 serology may include monitoring population-level transmission to determine appropriate 70 interventions, post-validation surveillance, opportunistic investigation of populations 71 using blood collected for other purposes, and fine-scale geographic targeting of control 72 measures.^{11–13} 73

IgG antibody responses to Ct antigens Pgp3 and CT694 are sensitive and 74 specific markers of Ct infection.^{14,15} Assays have demonstrated consistency across 75 platforms (multiplex bead, enzyme-linked immunosorbent, lateral flow),^{16,17} robust 76 seropositivity cutoffs,¹⁸ and high repeatability.¹⁹ Of the two antigens, Pgp3 appears to 77 elicit a stronger and more durable response and is collected in most trachoma serology 78 surveys.²⁰ In epidemiologic studies, investigators have observed alignment between 79 population-level summaries of antibody response and other trachoma markers, 80 including the presence of Ct DNA, as determined by PCR, and the active trachoma sign 81 trachomatous inflammation—follicular (TF). Individual studies suggest age-dependent 82

seroprevalence curves rise steeply with age among children in trachoma-endemic 83 communities ^{14,15} and are flat in communities that have eliminated trachoma.^{21–23} IgG 84 responses to Pgp3 can be measured from dried blood spots and have the potential to 85 be scaled through integration in multiplex surveillance strategies with other infectious 86 pathogens.²⁴ Key next steps to advance the use of serology to monitor trachoma 87 88 programs are to benchmark serology against independent measures of transmission, notably PCR, and to formalize the analytic approaches used to summarize trachoma 89 90 antibody data.

91 Here, we collated IgG antibody, infection, and clinical data from 14 populations in five countries across a gradient of trachoma transmission intensities that ranged from 92 hyper-endemic to post-elimination. Due to the shortcomings of clinical signs, we used 93 PCR as the primary marker of trachoma activity, with TF as a secondary indicator to 94 contextualize serological estimates. We hypothesized that population-level summaries 95 of trachoma antibody measurements would follow a consistent path toward elimination, 96 characterized by flattening of age-seroprevalence curves and a corresponding decline 97 in seroconversion rates. We also hypothesized that different seroepidemiologic 98 99 summary measures (e.g. seroprevalence, seroconversion rates) would be consistent with one another and align similarly with population-level transmission. We completed a 100 series of analyses to test these hypotheses and in doing so, develop robust analytic 101 102 methods for trachoma serology as we approach the elimination endgame.

103

104

105 **Results**

106 Study populations and settings

107 We compiled serological, molecular, and clinical measurements collected between 2012 and 2019 across nine studies in five countries (Supplementary Table 1) 108 ^{4,25–32}. When possible, measurements within the same study were stratified into 109 populations corresponding to trachoma evaluation units, resulting in 14 study 110 111 populations. All studies were conducted in Africa and represented a gradient of trachoma transmission from hyper-endemic transmission to post-elimination. 112 Measurements were taken at a single time point or annually with the exception of 113 Dosso, Niger, where visits occurred every six months for the first year and annually 114 115 thereafter. Due to changing transmission and/or interventions over time in some studies, analyses included only the most recent round of measurements for each population. We 116 analyzed sampling clusters with 15 or more serological measurements, a total of 459 117 clusters. The median number of children contributing information per cluster was 40 118 (interquartile range: 32–48) (Supplementary Fig. 1), for a total of 19,811 serological 119 measurements. Eleven studies included children aged 1-9 years, and three studies 120 focused on children aged 1–5 years (Supplementary Fig. 2). 121

We generated population-level summaries using the median and range across clusters and observed wide variation in seroprevalence (median: 7%; range: 0–54%), PCR prevalence (median: 3%; range: 0–26%), and TF prevalence (median: 6%; range: 0–56%) (**Fig. 1**). PCR, a measure of current infection, may disappear rapidly following MDA ³³. Among clusters with MDA in the past year, the median PCR prevalence was 0%, while among clusters without recent MDA, PCR prevalence was 12%. Cluster-level

128	estimates within the same population were often variable, likely a combination of
129	heterogeneity in disease transmission and stochasticity due to smaller sample sizes.
130	Across the gradient of transmission intensities, population-level summaries of
131	seroprevalence aligned with PCR and TF prevalence (Fig. 1).
132	
133	Charting progress toward elimination using age-structured seroprevalence and
134	seroconversion rates
135	We estimated age-dependent seroprevalence curves using semiparametric
136	splines and seroconversion rates from age-structured seroprevalence (Methods).
137	Across populations, seroconversion rates ranged from 0 to 15 per 100 person-years
138	(median: 1.7) using a catalytic model without seroreversion (Fig. 2). Consistent with our
139	hypothesis, we observed that age-seroprevalence curves were flatter and
140	seroconversion rates were lower in areas with lower PCR prevalence. Age-
141	seroprevalence curves rose steeply in settings with high levels of infection such as Wag
142	Hemra and Andabet, Ethiopia, reaching >50% seroprevalence by age 9 years. In
143	contrast, in populations with flatter curves (<10% seroprevalence by age 9 years,
144	seroconversion rate <1 per 100 person-years), PCR prevalence was 0% when
145	measured (Woreta town and Alefa, Ethiopia). Among populations with moderately
146	increasing age-seroprevalence curves, roughly corresponding to seroconversion rates
147	between 1 and 5 per 100 person-years, PCR prevalence ranged from 0 (Dera, Ethiopia)
148	to 1.9% (Kongwa, Tanzania 2018).
149	

150

151 Agreement between serology-based summary measures

Summary statistics estimated from age-seroprevalence curves provide 152 additional, useful summary measures of transmission.^{9,34} Population-level summaries of 153 IgG responses include geometric mean IgG levels, seroprevalence, and seroconversion 154 rates — each progression from IgG levels to seroconversion rates relies on additional 155 156 model assumptions and analysis complexity (details in Methods). In the estimation of seroconversion rates from age-structured seroprevalence, we considered a range of 157 model complexity that included a catalytic model (corresponding to a susceptible-158 159 infected-recovered, SIR, model), a reversible catalytic model allowing for seroreversion (corresponding to a susceptible-infected-susceptible, SIS, model), and a 160 semiparametric hazard model that allowed for age-varying seroconversion rates. 161 A key question for elimination programs is whether the additional complexity in 162 analysis leads to more useful information for identifying populations with ongoing ocular 163 Ct transmission. We estimated each summary at the sampling cluster and population 164 levels across the 14 study populations and found high correlation between all measures 165 (Spearman $\rho \ge 0.88$ for all comparisons, **Fig. 3**). Cluster-level seroprevalence was 166 167 strongly, linearly related with geometric mean IgG levels on the log_{10} scale (**Fig. 3a**), and there was a strong, non-linear relationship between seroprevalence and the 168 169 seroconversion rate (Fig. 3b). Catalytic models that allowed for seroreversion shifted 170 seroconversion rates up, particularly for clusters with a seroconversion rate greater than 20 per 100 person-years but had minimal influence on estimates at intermediate and 171 172 lower levels of transmission (Fig. 3c). Similarly, seroprevalence was tightly linked with 173 seroconversion rates that allowed for seroreversion in settings with lower prevalence,

and greater dispersion was observed in hyperendemic populations (Fig. 3d). The most 174 complex model, a semiparametric proportional hazards spline model that allowed for an 175 age-varying seroconversion rate, required more data than would be typically available at 176 the sampling cluster level and thus could only be estimated at the population level 177 where its estimates aligned closely with a simpler, constant rate model (Supplementary 178 179 Fig. 3). These results show that all serologic summary measures provide similar information when averaged at the cluster or population level across all ranges of 180 transmission and particularly at lower levels of transmission. 181 182 Comparing trachoma indicators in the presence and absence of MDA 183 As most trachoma program interventions act to clear infection or reduce its 184 transmission, we sought summaries that could capture variation in populations' Ct 185 infection burden. Seroprevalence and PCR prevalence aligned closely at the population 186 level (r = 0.88; 95% CI: 0.77–0.93, Fig. 4a). At both the cluster- and population-levels, 187 seroprevalence was almost always greater than or equal to PCR prevalence, 188 underscoring the sensitivity of seroprevalence as a measure of current or past infection. 189 190 However, PCR prevalence was highly variable across levels of seroprevalence; low PCR prevalence in the context of high seroprevalence may imply previously high levels 191 of infection that had been controlled by MDA or other interventions. Relationships 192 193 between TF and PCR prevalence were similar (population-level r = 0.92; 95% CI: 0.73– 0.96, Fig. 4b). 194 As shown in prior work,³⁵ TF and seroprevalence were more strongly correlated 195

196 with PCR prevalence in the absence of MDA in the past year (**Fig. 4a, 4b**). In the

absence of MDA, the relationship between seroprevalence and PCR prevalence was
nearly linear, particularly in high transmission settings. In the presence of recent MDA,
correlations between trachoma indicators weakened presumably because IgG and TF
prevalence remain elevated as durable indicators of trachoma even after infections
have been reduced through MDA.

202 We also stratified the analyses by child age and observed similar correlations between indicators among children aged 1–9 years compared to children aged 1–5 203 years (Fig. 5). When summarizing IgG responses as seroconversion rate instead of 204 205 seroprevalence, overall results and subgroup results by recent MDA and age group were similar (Supplementary Fig. 4), reflecting the tight correlation between serologic 206 summaries (Fig. 3). Our results show that serologic summaries align with PCR 207 prevalence as well or better than TF, the current programmatic indicator, and that 208 serology performs well even among preschool aged children. In populations that have 209 210 recently undergone MDA, IgG and TF will likely remain elevated even as infection prevalence falls. 211

212

Assessing serologic thresholds for elimination of infections

Due to the wide variability in trachoma indicators both within and between populations, we used a nonparametric approach to evaluate potential serologic summary thresholds. Based on the alignment between seroprevalence and PCR at the cluster level and the relatively large number of clusters, we assessed sensitivity and specificity using cluster-level values. At each potential threshold, sensitivity and specificity were calculated across the 281 clusters with PCR measurements, 99 of

which had at least one infection detected by PCR. Although presence of a single
infection is a stringent threshold, an appropriate level of PCR prevalence required to
prevent blindness due to trachoma has yet to be established. Under this definition, a
threshold with high sensitivity would result in more infected clusters being detected,
while a threshold with high specificity might imply less unnecessary intervention. While
overtreatment should be avoided, we focused on thresholds with high sensitivity with
the goal of elimination in mind.

There was good classification of clusters with and without Ct infections based on 227 228 either seroprevalence or seroconversion rates (AUC=0.92). Thresholds of 13.5% seroprevalence (Fig. 6, Supplementary Table 2) or 2.75 seroconversions per 100 229 person-years (Supplementary Fig. 5, Supplementary Table 3) had 90% sensitivity 230 and 69-75% specificity to identify clusters with any PCR-detected infections. Thresholds 231 of 22.5% seroprevalence and 5.75 seroconversions per 100 person-years had 80% 232 sensitivity and 92-93% specificity. Thresholds were conservative when compared 233 against population-specific sensitivity estimates in high transmission settings, but 234 sensitivity dropped quickly in populations with very few infected clusters (n=4 in 235 236 Chikwawa, Malawi and n=6 in Mchinji, Malawi) (Fig. 6a).

The overall analysis included all clusters regardless of age group. In a sensitivity analysis that included only children aged 1–5 years, classification of clusters with and without *Ct* infections was almost identical to the main analysis (AUC=0.92), and thresholds of 12.5% seroprevalence and 2.75 conversions per 100 person-years had 90% sensitivity and 69-71% specificity to identify clusters with any PCR-detected infections (**Supplementary Fig 6, Supplementary Table 4, Supplementary Table 5**).

243	In a supplementary assessment of the thresholds, we applied them to
244	populations with very low trachoma prevalence that were not included in the threshold
245	analysis because cluster-level PCR results were unavailable (Dosso, Alefa, and Woreta
246	town, see Figs. 1 and 2). District-level PCR from Alefa and Woreta town were estimated
247	to be 0%, and a recent study from the same population in Dosso found no Ct in pooled
248	metagenomic testing of ocular swabs. ³⁶ In these three populations, 98% of clusters
249	(60/61) fell below the serologic thresholds for 90% sensitivity, supporting the
250	interpretation of low levels of infection below the estimated thresholds.

251

252 **Discussion**

Using antibody measurements from 14 populations across a gradient of Ct 253 transmission intensity, we demonstrated that IgG Pgp3 age-seroprevalence curves 254 flatten and seroprevalence and seroconversion rates progress toward zero as 255 256 populations approach elimination, consistent with biological assumptions and observations across other pathogens.^{34,37} To our knowledge, this is the largest synthesis 257 of Ct serology and infection data spanning globally relevant transmission settings from 258 hyper-endemic to elimination. Summaries of IgG responses to Ct antigen Pgp3 among 259 children aged 1-9 years aligned similarly with PCR prevalence and with one another at 260 both the cluster- and population-levels, indicating that cluster-level Pgp3 summaries 261 reflect variation in Ct infections and ongoing transmission. Combining information 262 across all populations, we found that thresholds of 13.5% seroprevalence and 2.75 263 264 seroconversions per 100 person-years identified clusters with any infection with high sensitivity (>90%) and moderate specificity (69 to 75%). We observed similar results 265

when analyses were restricted to children aged 1–5 years, an age group that is 266 potentially easier to sample in household surveys as they are not yet in school. 267 We demonstrated that seroprevalence and seroconversion rates perform as well 268 or better as correlates of population levels of infection compared with clinical TF, and 269 270 serology is arguably more objective, granular, and scalable for surveillance. Although 271 clinical signs are important markers of disease progression, MDA is targeted towards Ct infections — if clinical signs continue to be present in the absence of antibody 272 responses, further investigation may be warranted to determine other potential causes 273 274 of inflammation. Compared to PCR, which also measures Ct infections, serology is costeffective, with simpler collection procedures and the opportunity to leverage banked 275 276 samples, and measures exposure over time versus at a single point, an advantage in low prevalence settings. 277

By focusing on parsimonious, generalizable methods, our aim was to present 278 seroepidemiologic approaches that could be easily applied and interpreted by trachoma 279 control programs. Trachoma programs currently rely on district-level estimates of active 280 trachoma, and this analysis may be extended to develop district-level thresholds as an 281 282 increasing number of district-level, population-based serological surveys become available. Cluster-level estimates, as investigated here, may be a promising alternative 283 284 to identify focal areas for intervention, particularly in combination with geostatistical methods to improve precision and project across unsurveyed regions.³⁸ 285

286 Programmatic decisions related to suspension or reinitiation of antibiotic MDA 287 primarily take place in low to intermediate transmission settings, and this study 288 demonstrates that the information serologic surveillance provides in such settings

should be robust to choice of summary statistic. Serological summaries of increasing 289 complexity were tightly correlated with one another, and the relationship was nearly 290 linear in settings with low to intermediate transmission (Fig. 3). Quantitative IgG 291 responses potentially provide information at very low levels of Ct transmission when 292 most children are seronegative,³⁹ but a challenge is that IgG responses are in arbitrary 293 294 units that may not be directly comparable across studies. Members of our team are developing a chimeric, monoclonal antibody to help facilitate direct comparison of 295 guantitative antibody levels across studies.¹² Seroprevalence and seroconversion rates 296 297 are standard transformations of the quantitative IgG response that are easier to compare across studies and labs. A potential drawback of seroprevalence and 298 seroconversion is that they may be sensitive to choice of the seropositivity cutoff, 299 potentially affecting programmatic decisions based on thresholds. In a sensitivity 300 analysis, we found that identification of clusters with Ct infection based on 301 302 seroprevalence and seroconversion rates were robust to large changes in the seropositivity cutoff (**Supplementary Fig 7**). The seroconversion rate is tightly linked to 303 the slope of the age-seroprevalence curve (details in Methods). Additionally, the 304 305 seroconversion rate implicitly adjusts for age (not guaranteed with mean IgG or seroprevalence) and can be interpreted as a measure of a pathogen's force of infection. 306 307 Although we did not consider complicated seroconversion models that allowed for 308 changes in transmission over time, such complexity may be less relevant when analyzing measurements from young children because their antibody responses reflect 309 recent infections.^{40–42} Our results support estimation of age-seroprevalence curves 310 311 among young children combined with estimation of seroconversion rates using a simple,

single-rate model to characterize trachoma transmission. Our findings demonstrate that
the slope of the age-seroprevalence curve and the seroconversion rate are sensitive
and moderately specific markers of population-level *Ct* infection. Seroprevalence is
another simple, robust summary measure that aligned with infections as well as
seroconversion rate, particularly in the absence of recent MDA, but care should be
taken to ensure similar age structure between populations to avoid bias.

We found that serologic summaries were sensitive indicators of Ct infection but 318 have only moderate specificity: antibody responses were nearly always present in 319 320 populations with infections, but the IgG signal persisted even if recent MDA reduced infection to low levels. This pattern suggests that populations requiring treatment will 321 rarely be missed by serology but further verification with PCR could prevent 322 overtreatment in the case of false positives. Because IgG responses to Pgp3 are 323 durable, age-seroprevalence curves and statistics estimated from them may reflect 324 325 historical transmission patterns and remain high despite low levels of infection resulting from control measures or secular trends. Restricting analysis to younger children (e.g., 326 children born after discontinuing antibiotic MDA) or carefully accounting for past MDA 327 328 treatments in the interpretation of antibody data may decrease false positives detected by IgG. At the cluster level, infections may also be missed due to small sample sizes. 329 330 Extending this work using a freedom-from-infection framework may inform appropriate cluster-level sample sizes for a desired level of uncertainty.⁴³ 331

Here, we focused on IgG among young children and its relationship with *Ct* infection to extend a previous study that combined nine trachoma serology surveys and compared IgG seroconversion rates with clinical indicators among people of all ages.⁴⁰

A focus on young children rather than all ages enabled us to simplify the modeling 335 approach used to estimate seroconversion rates under the assumption that 336 transmission was approximately stable over the age range. We focused on the 337 relationship between serology and PCR infection to assess the utility of serology to 338 monitor differences in pathogen transmission. The earlier synthesis compared indicators 339 340 at the district level, which is the current scale of decision making for elimination programs. A caveat of the approach used in this study to identify serology thresholds to 341 identify the presence of Ct infections is that we used clusters as the unit of analysis — a 342 343 much finer spatial scale than district. We felt a similar, non-parametric threshold analysis at the district (study) level would not be informative with only 11 studies that 344 included Ct infection measurements (Fig. 1), versus 281 unique clusters (Fig. 6). Future 345 estimates of district-level serology thresholds for elimination, using the same summary 346 statistics but potentially using a different approach to identify thresholds, would be a 347 useful extension. 348

This work is subject to limitations. First, the data we analyzed were compiled 349 from different previously published studies and sites that were available to us. Our 350 351 results may not be representative of all populations with ongoing trachoma transmission. For example, the included studies come from five countries in Africa, but 352 353 trachoma continues to be endemic in the other regions of Africa, Latin America, Asia, and the Pacific Islands.⁴⁴ As a secondary analysis, our work was also affected by design 354 features of individual studies, such as site selection in RCTs, which were typically not 355 356 selected using probability samples. Second, all models used to estimate 357 seroconversion, except for the semiparametric spline model, assumed homogeneity of

seroconversion rate over age and time. For most studies, we expected stable 358 transmission among 1–9-year-olds in the recent past. Our analysis used an estimate of 359 seroreversion from one longitudinal cohort.⁴⁵ but data beyond this cohort is limited; 360 however, based on a sensitivity analysis, no single seroreversion value resulted in the 361 best model fit across populations (Supplementary Fig. 8). Finally, we were unable to 362 evaluate more specific subgroups, such as populations with different MDA histories or 363 populations experiencing recrudescence, due to limited data. Based on the variability 364 observed between populations, refinement of thresholds may be warranted as more 365 366 data are collected.

In conclusion, IgG responses to Ct antigen Pgp3 among 1–9-year-olds aligned 367 closely with ongoing transmission as measured by PCR and TF across a range of 368 trachoma endemicity settings. Consistent with patterns observed across other 369 pathogens, age-dependent Pgp3 seroprevalence curves became flatter and 370 seroconversion rates declined to zero as populations approached elimination -371 providing a coherent framework for monitoring Ct transmission in seroepidemiologic 372 studies. Serologic summaries estimated via a range of model complexity were sensitive 373 374 markers of ocular chlamydial infection and were consistent with one another, implying 375 that simpler approaches are likely sufficient to capture variation in transmission. These results support use of serologic surveys to inform trachoma programs as populations 376 377 approach elimination.

378

380 Methods

381 Contributing studies

We gathered data from published trachoma serology surveys, with an emphasis 382 on IgG antibody responses to Pgp3 collected among children aged 1-9 years and 383 relatively recent reports (Supplementary Table 1). All studies were conducted between 384 2012 and 2019. Children below the age of 1 year were excluded to mitigate the 385 influence of maternal antibodies. Based on the original study designs, measurements in 386 Matameve, Niger (PRET) and Wag Hemra, Ethiopia (TAITU) were restricted to children 387 aged under 6 years; in Dosso, Niger (MORDOR), the study was limited to children aged 388 under 5 years; and in Alefa, Andabet, Dera, and Woreta town, Ethiopia, infections were 389 measured among children aged 1-5-years, while serology and TF were measured 390 among children aged 1-9-year. For measurements collected as part of a population-391 based surveys, multi-level cluster random sampling was used. For measurements 392 393 collected as part of a randomized controlled trial, we combined data across arms unless otherwise noted (e.g., stratification by recent MDA). Due to changing transmission 394 and/or control interventions in studies with repeated cross-sectional data (WUHA in 395 Wag Hemra, Ethiopia; Kongwa, Tanzania from 2012-2015; MORDOR in Dosso, Niger), 396 we included only the most recent year of measurements with serology, and PCR 397 measurements if available, for each population. We excluded clusters with fewer than 398 15 children measured to ensure sufficient information to estimate cluster level means 399 (n=22 clusters excluded, reduced from 481 to 459). 400

401 Details of serological, clinical, and PCR measurements can be found in the 402 published reports for each study ^{4,25–32}. In all but one study, dried blood spots were

analyzed for IgG antibodies to Pgp3 using a multiplex bead assay on a Luminex 403 platform and were reported as median fluorescence intensity minus background (MFI-404 bg), and seropositivity cutoffs were generated using receiver operator characteristic 405 (ROC) methods ¹⁴. In Malawi, dried blood spots were tested for IgG antibodies against 406 Pgp3 using ELISA, and the seropositivity cutoff was determined based on a finite 407 mixture model ³¹. ELISA-based population-level measurements of Pgp3 have been 408 shown to have good agreement with multiplex bead assays ⁴⁶. We used cutoffs defined 409 by each study to assign seropositivity status. To assess robustness to seropositivity 410 411 cutoffs, we compared seroprevalence and seroconversion rate calculated across a range of arbitrary cutoffs for four study populations at different levels of trachoma 412 prevalence (Supplementary Fig. 7). Clinical disease was assessed by trained field 413 graders according to the WHO simplified grading system ⁴⁷, which defines TF as the 414 presence of five or more follicles which are (a) at least 0.5 mm in diameter and (b) 415 located in the central part of the upper tarsal conjunctiva. Conjunctival swabs were 416 assessed for Ct DNA using PCR. In 5 out of 7 studies with PCR measurements, cluster-417 level prevalence was estimated from individual-level results ^{29–31,48,49}; in one study 418 419 (PRET), cluster-level prevalence was estimated from pooled results using maximum likelihood methods ^{50,51}. For Andabet, Dera, Woreta town, and Alefa, Ethiopia, Ct 420 infection prevalence was estimated at the district level from pooled results using 421 maximum likelihood methods ²⁶. 422

423 Cluster-level prevalence was calculated as the number of children who were 424 sero-, PCR- or TF-positive divided by the number of children tested for the respective 425 outcome. When possible, "populations" were defined by districts or evaluation units

426	currently used for trachoma monitoring. Population-level prevalence estimates were
427	defined as the median value across clusters. Age-seroprevalence curves were
428	estimated by pooling all measurements at the population level, calculating
429	seroprevalence for one-year age groups, and fitting cubic spline models to generate
430	smooth trend lines.

431

432 Estimating serology-based summary measures

We summarized IgG responses as geometric mean IgG levels, seroprevalence, 433 and seroconversion rates from several models. The seroconversion rate from a current 434 status, single-rate catalytic model assuming no seroreversion is closely tied to the slope 435 of age-seroprevalence curve.⁵² Specifically, the hazard (seroconversion rate) is equal to 436 the slope of the age-seroprevalence curve divided by the complement of the 437 seroprevalence at age a. It can be shown that the seroconversion rate based on this 438 model can be estimated as the exponentiated intercept from a generalized linear model 439 with binomial error structure and a complementary log-log link: ⁵³ 440

441
$$\log[-\log(1 - P(Y = 1 | A))] = \log(\lambda) + \log(A)$$

where Y represents individual level serostatus (1: seropositive, 0: seronegative or equivocal), *A* is the child's age in years, and λ is the seroconversion rate. The seroconversion rate provides an estimate of the force of infection, an epidemiological parameter that denotes the rate at which susceptible individuals in the population become infected.

447 Next, we extended this model to allow for seroreversion. Cross-sectional data do
 448 not contain sufficient information to reliably estimate both seroreversion and

seroconversion rates.⁵⁴ Therefore, we fit a binomial maximum likelihood model for
 seroconversion with fixed seroreversion rates ranging from 0.02 to 0.20 per person vear:^{21,26,40}

$$P(Y = 1 | A) = \frac{\lambda}{\lambda + \rho} [1 - \exp(-(\lambda + \rho) \times A)]$$

where ρ is the assumed seroreversion rate. In our main analyses, we assumed a
seroreversion rate of 6.6 per 100 person-years based on a longitudinal cohort in
Kongwa, Tanzania monitored in the absence of MDA ⁴⁵, which is likely conservative for
higher transmission settings. No level of seroreversion consistently provided the best fit
across populations (Supplementary Fig. 8). This model did not converge in several
clusters (6 out of 416 clusters with seroprevalence >0%, or 1.4%), which often
contained few seropositive children.

Finally, we fit semiparametric spline models to allow seroconversion to vary by age.⁵² We fit this model only at the population level, as it requires more data than are typically available at the sampling cluster level (around 20-40 children). We fit a generalized linear model with complementary log-log link for seropositivity:

464
$$\log[-\log(1 - P(Y = 1 | A))] = g(A)$$

where g(A) is a flexible function for age modeled using cubic splines. To estimate the average seroconversion rate in each population, λ , we integrated over age using predictions from the model. We used the relationship between the hazard $\lambda(a)$ and cumulative incidence F(a), where F(a) is the predicted seroprevalence at age a (details in ³⁷).

470
$$\lambda = \int_{a_1}^{a_2} \lambda(a) da = \frac{\log[1 - F(a_1)] - \log[1 - F(a_2)]}{a_2 - a_1}$$

471

472	Comparison of different trachoma indicators
473	We used the Pearson correlation coefficient to compare serologic summaries
474	and TF prevalence with PCR prevalence at the population and cluster levels. We
475	conducted this analysis across all populations with PCR measurements and explored
476	the impact of contextual factors by stratifying clusters into subgroups defined by MDA in
477	the past year (yes / no) and age range (1–9-year-olds / 1–5-year-olds).
478	We used the Spearman rank correlation coefficient to compare different serologic
479	summaries with one another at the cluster level, allowing for non-linearity in the
480	relationships. We estimated simultaneous confidence intervals from a cubic spline to
481	summarize the relationship between markers at the cluster level, including a random
482	effect for study to allow for correlated measures within-study.
483	
484	Serologic thresholds for elimination
485	We used a non-parametric approach to assess thresholds of seroprevalence or
486	seroconversion rates to classify clusters without PCR infections. For overall estimates,
487	we combined clusters from all populations with PCR measurements, for a total of 281
488	clusters and 99 clusters with at least one PCR-detected infection. We defined a range of
489	cutoffs covering nearly all cluster-level estimates (0 to 100% for seroprevalence, 0 to 50
490	per 100 person-years for seroconversion rate) and divided the range into 200
491	increments. At each step, we calculated sensitivity as the proportion of clusters with
492	serology values above the threshold among clusters with any infection, and specificity

as the proportion of clusters with serology value less than or equal to the threshold

494	among clusters with zero infections detected. We identified the highest thresholds
495	achieving at least 90% and 80% sensitivity. We also presented these results as receiver
496	operating characteristic (ROC) curves and calculated overall area-under-the-curve
497	(AUC). We calculated sensitivity, specificity, and the ROC curve for each population
498	separately.
499	
500	Data availability
501	R version 4.2.2 (2022-10-21, "Innocent and Trusting") was used for this

(note: during peer review we are finalizing agreements to provide de-identified data):
https://osf.io/e6j5a/.

analysis.⁵⁵ De-identified data and all code to reproduce this work are publicly available

505

502

506 Acknowledgements

Ethics statement. The secondary analysis protocol was reviewed and approved 507 by the Institutional Review Board at the University of California, San Francisco (Protocol 508 509 #20-33198). All primary data that contributed to the analysis was collected after obtaining informed consent from all participants or their guardians under separate 510 human subjects research protocols in accordance with the Declaration of Helsinki. 511 512 Conflict of interest statement. The authors have no conflicts of interest to report. The authors alone are responsible for the views expressed in this article, and they do 513 not necessarily represent the views, decisions, or policies of the institutions with which 514 they are affiliated. 515

- 516 *Funding statement.* This work was supported by the National Institute of Allergy
- and Infectious Diseases (R01-AI158884 to B.F.A.). AWS is a staff member of the World
- 518 Health Organization.
- 519 *Disclaimer*. The findings and conclusions in this article are those of the authors
- and do not necessarily represent the official position of the National Institutes of Health
- 521 or the Centers for Disease Control and Prevention. Use of trade names is for
- identification only and does not imply endorsement by the Public Health Service or by
- 523 the U.S. Department of Health and Human Services.
- 524
- 525 Author contributions (<u>CRediT taxonomy</u>).
- 526 Conceptualization: CT, AWS, DLM, SDN, PJL, BFA
- 527 Data curation: CT, DLM, BFA
- 528 Formal analysis: CT, BFA
- 529 Funding acquisition: BFA, DLM
- 530 Investigation: CT, BFA
- 531 Methodology: CT, BFA
- 532 Project administration: DLM, BFA
- 533 Resources: All authors
- 534 Software: CT, BFA
- 535 Supervision: AWS, DLM, SDN, SKW, TML, JDK, PJL
- 536 Validation: CT, BG, DLM, BFA
- 537 Visualization: CT, BFA
- 538 Writing original draft preparation: CT, BFA
- 539 Writing review & editing: All authors
- 540
- 541
- 542
- 543

544 **References**

- World Health Organization. Ending the neglect to attain the sustainable development goals:
 a roadmap for neglected tropical diseases 2021-2030.
- 548 https://apps.who.int/iris/handle/10665/361856 (2020).
- Taylor, H. R., Burton, M. J., Haddad, D., West, S. & Wright, H. Trachoma. *The Lancet* **384**, 2142–2152 (2014).
- Keenan, J. D. *et al.* Clinical Activity and Polymerase Chain Reaction Evidence of Chlamydial Infection after Repeated Mass Antibiotic Treatments for Trachoma. *Am. J. Trop. Med. Hyg.* 82, 482–487 (2010).
- Amza, A. *et al.* Community-level Association between Clinical Trachoma and Ocular
 Chlamydia Infection after MASS Azithromycin Distribution in a Mesoendemic Region of
 Niger. *Ophthalmic Epidemiol.* 26, 231–237 (2019).
- Ramadhani, A. M., Derrick, T., Macleod, D., Holland, M. J. & Burton, M. J. The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment. *PLoS Negl. Trop. Dis.* **10**, e0005080 (2016).
- 6. Assaad, F. A. & Maxwell-Lyons, F. Systematic observer variation in trachoma studies. *Bull. World Health Organ.* 36, 885–900 (1967).
- Tielsch, J. M. *et al.* Trachoma grading: observer trials conducted in southern Malawi. *Br. J. Ophthalmol.* **71**, 371–374 (1987).
- Gebresillasie, S. *et al.* Inter-Rater Agreement between Trachoma Graders: Comparison of
 Grades Given in Field Conditions versus Grades from Photographic Review. *Ophthalmic Epidemiol.* 22, 162–169 (2015).
- 567 9. Corran, P., Coleman, P., Riley, E. & Drakeley, C. Serology: a robust indicator of malaria
 568 transmission intensity? *Trends Parasitol.* 23, 575–582 (2007).
- 569 10. Stringhini, S. *et al.* Seroprevalence of anti-SARS-CoV-2 lgG antibodies in Geneva,
 570 Switzerland (SEROCoV-POP): a population-based study. *Lancet Lond. Engl.* **396**, 313–319
 571 (2020).
- 572 11. Woodhall, S. C. *et al.* Advancing the public health applications of Chlamydia trachomatis
 573 serology. *Lancet Infect. Dis.* 18, e399–e407 (2018).
- 12. Martin, D. L. *et al.* The use of serology for trachoma surveillance: Current status and priorities for future investigation. *PLoS Negl. Trop. Dis.* **14**, e0008316 (2020).
- 13. Cooley, G. M. *et al.* No Serological Evidence of Trachoma or Yaws Among Residents of
 Registered Camps and Makeshift Settlements in Cox's Bazar, Bangladesh. *Am. J. Trop. Med. Hyg.* **104**, 2031–2037 (2021).
- 579 14. Goodhew, E. B. *et al.* CT694 and pgp3 as Serological Tools for Monitoring Trachoma
 580 Programs. *PLoS Negl. Trop. Dis.* 6, e1873 (2012).
- 15. Goodhew, E. B. *et al.* Longitudinal analysis of antibody responses to trachoma antigens
 before and after mass drug administration. *BMC Infect. Dis.* 14, 3154 (2014).
- 16. Gwyn, S. *et al.* Comparison of Platforms for Testing Antibody Responses against the
 Chlamydia trachomatis Antigen Pgp3. *Am. J. Trop. Med. Hyg.* 97, 1662–1668 (2017).
- 17. Wiegand, R. E. *et al.* Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3. *Sci. Rep.* **8**, 4232 (2018).
- 18. Migchelsen, S. J. *et al.* Defining Seropositivity Thresholds for Use in Trachoma Elimination
 Studies. *PLoS Negl. Trop. Dis.* **11**, e0005230 (2017).
- 19. Kaur, H., Dize, L., Munoz, B., Gaydos, C. & West, S. K. Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. *J. Microbiol. Methods* 147, 56–58 (2018).

- Wang, J. *et al.* A Genome-Wide Profiling of the Humoral Immune Response to Chlamydia
 trachomatis Infection Reveals Vaccine Candidate Antigens Expressed in Humans. *J. Immunol.* 185, 1670–1680 (2010).
- 595 21. Martin, D. L. *et al.* Serology for Trachoma Surveillance after Cessation of Mass Drug 596 Administration. *PLoS Negl. Trop. Dis.* **9**, e0003555 (2015).
- 597 22. Pant, B. P. *et al.* Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study 598 from the Nepal National Trachoma Program. *PLoS Negl. Trop. Dis.* **10**, e0004462 (2016).
- West, S. K. *et al.* Can We Use Antibodies to Chlamydia trachomatis as a Surveillance Tool
 for National Trachoma Control Programs? Results from a District Survey. *PLoS Negl. Trop. Dis.* 10, e0004352 (2016).
- Arnold, B. F., Scobie, H. M., Priest, J. W. & Lammie, P. J. Integrated Serologic Surveillance
 of Population Immunity and Disease Transmission. *Emerg. Infect. Dis.* 24, 1188–1194
 (2018).
- 605 25. Kim, J. S. *et al.* Community-level chlamydial serology for assessing trachoma elimination in trachoma-endemic Niger. *PLoS Negl. Trop. Dis.* **13**, (2019).
- 26. Nash, S. D. *et al.* Population-Based Prevalence of Chlamydia trachomatis Infection and
 Antibodies in four Districts with Varying Levels of Trachoma Endemicity in Amhara, Ethiopia.
 Am. J. Trop. Med. Hyg. (2020) doi:10.4269/ajtmh.20-0777.
- 27. Wittberg, D. M. *et al.* WASH Upgrades for Health in Amhara (WUHA): study protocol for a cluster-randomised trial in Ethiopia. *BMJ Open* **11**, e039529 (2021).
- 28. Keenan, J. D. *et al.* Azithromycin to Reduce Childhood Mortality in Sub-Saharan Africa. *N. Engl. J. Med.* 378, 1583–1592 (2018).
- 614 29. Wilson, N. *et al.* Evaluation of a Single Dose of Azithromycin for Trachoma in Low-615 Prevalence Communities. *Ophthalmic Epidemiol.* **26**, 1–6 (2019).
- 30. Odonkor, M. *et al.* Serology, infection, and clinical trachoma as tools in prevalence surveys
 for re-emergence of trachoma in a formerly hyperendemic district. *PLoS Negl. Trop. Dis.* **15**,
 e0009343 (2021).
- Burr, S. E. *et al.* Pgp3 seroprevalence and associations with active trachoma and ocular
 Chlamydia trachomatis infection in Malawi: cross-sectional surveys in six evaluation units.
 PLoS Negl. Trop. Dis. **13**, e0007749 (2019).
- 32. Hammou, J. *et al.* Post-Validation Survey in Two Districts of Morocco after the Elimination of
 Trachoma as a Public Health Problem. *Am. J. Trop. Med. Hyg.* **106**, 1370–1378 (2022).
- 624 33. Solomon, A. W. et al. Trachoma. Nat. Rev. Dis. Primer 8, 1–20 (2022).
- 34. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
 malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* 11,
 e0005616 (2017).
- 35. Tedijanto, C. *et al.* Predicting future community-level ocular Chlamydia trachomatis infection
 prevalence using serological, clinical, molecular, and geospatial data. *PLoS Negl. Trop. Dis.* 16, e0010273 (2022).
- 36. Arzika, A. M. *et al.* Effect of Biannual Mass Azithromycin Distributions to Preschool-Aged
 Children on Trachoma Prevalence in Niger: A Cluster Randomized Clinical Trial. *JAMA Netw. Open* 5, e2228244 (2022).
- Arnold, B. F. *et al.* Fine-scale heterogeneity in *Schistosoma mansoni* force of infection
 measured through antibody response. *Proc. Natl. Acad. Sci.* **117**, 23174–23181 (2020).
- 38. Amoah, B. *et al.* Model-based geostatistics enables more precise estimates of neglected
 tropical-disease prevalence in elimination settings: mapping trachoma prevalence in
 Ethiopia. *Int. J. Epidemiol.* 51, 468–478 (2022).
- 39. Arnold, B. F. *et al.* Measuring changes in transmission of neglected tropical diseases,
- malaria, and enteric pathogens from quantitative antibody levels. *PLoS Negl. Trop. Dis.* 11,
 e0005616 (2017).

- 40. Pinsent, A. *et al.* The utility of serology for elimination surveillance of trachoma. *Nat. Commun.* 9, 5444 (2018).
- 644 **41**. Yman, V. *et al.* Antibody acquisition models: A new tool for serological surveillance of 645 malaria transmission intensity. *Sci. Rep.* **6**, 19472 (2016).
- 42. Sepúlveda, N., Stresman, G., White, M. T. & Drakeley, C. J. Current Mathematical Models
 for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and
 Eradication. *J. Immunol. Res.* 2015, 1–21 (2015).
- 43. Michael, E. *et al.* Substantiating freedom from parasitic infection by combining transmission model predictions with disease surveys. *Nat. Commun.* **9**, 4324 (2018).
- 44. Renneker, K. K. *et al.* Global progress toward the elimination of active trachoma: an analysis of 38 countries. *Lancet Glob. Health* **10**, e491–e500 (2022).
- 45. West, S. K. *et al.* Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area. *Sci. Rep.* **8**, 3520 (2018).
- 46. Gwyn, S. *et al.* The Performance of Immunoassays to Measure Antibodies to the Chlamydia
 trachomatis Antigen Pgp3 in Different Epidemiological Settings for Trachoma. *Am. J. Trop. Med. Hyg.* (2021) doi:10.4269/ajtmh.21-0541.
- 47. Thylefors, B., Dawson, C. R., Jones, B. R., West, S. K. & Taylor, H. R. A simple system for
 the assessment of trachoma and its complications. *Bull. World Health Organ.* 65, 477–483
 (1987).
- 48. Melo, J. S. *et al.* Targeted antibiotics for trachoma: a cluster-randomized trial. *Clin. Infect. Dis.* ciab193 (2021) doi:10.1093/cid/ciab193.
- 49. Aragie, S. *et al.* Water, sanitation, and hygiene for control of trachoma in Ethiopia (WUHA):
 a two-arm, parallel-group, cluster-randomised trial. *Lancet Glob. Health* 10, e87–e95 (2022).
- 50. Ray, K. J. *et al.* Estimating Community Prevalence of Ocular *Chlamydia trachomatis*Infection using Pooled Polymerase Chain Reaction Testing. *Ophthalmic Epidemiol.* 21, 86–
 91 (2014).
- 51. Amza, A. *et al.* A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma
 Treatment to Children. *Clin. Infect. Dis.* 64, 743–750 (2017).
- 52. Hens, N., Shkedy, Z., Aerts, M., Damme, C. F. P. V. & Beutels, P. Modeling Infectious
 Disease Parameters Based on Serological and Social Contact Data. (Springer, 2012).
- 53. Jewell, N. P. & Laan, M. V. Generalizations of current status data with applications. *Lifetime Data Anal.* **1**, 101–109 (1995).
- 54. Arnold, B. F. *et al.* Enteropathogen antibody dynamics and force of infection among children in low-resource settings. *eLife* **8**, e45594 (2019).
- 55. R Core Team. *R: A language and environment for statistical computing.* (R Foundation for Statistical Computing, 2020).
- 56. Hammou, J. *et al.* In Morocco, the elimination of trachoma as a public health problem becomes a reality. *Lancet Glob. Health* **5**, e250–e251 (2017).
- 680



Abbreviations: n = number of individuals measured; m = number of clusters

* Estimates collected in population-based prevalence survey

† Serology, PCR, and TF measured among 1-5-year-olds

‡ PCR prevalence estimated only at district-level among 1-5-year-olds

Figure 1. Seroprevalence, PCR positivity, and TF prevalence across study populations. Clusterlevel prevalence estimates are represented by colored lines, and overlaid boxplots show the median, interquartile range, and range (excluding outliers defined as points more than 1.5 times the interquartile range from the 25th or 75th percentile) for each population. Study site, country, study name (if applicable), and year of data collection are listed on the left with number of individuals (n) and number of clusters (m) included in the analyses. For studies with only district-level estimates of PCR prevalence the mean is indicated with a circle rather than box plot. NA marks studies that did not measure PCR or trachomatous inflammation—follicular (TF). Study populations are arranged in descending order of seroconversion rates, presented in Figure 2.



Abbreviations: PY = person-years; ETH = Ethiopia; NER = Niger; TZA = Tanzania; MWI = Malawi; MAR = Morocco

Figure 2. Age-dependent seroprevalence curves, modeled seroconversion rates, and PCR prevalence across study populations. Cubic splines fit to seroprevalence by age are shown in the left plot. Cluster-level seroconversion rates and PCR prevalence estimates are represented by colored lines, and overlaid boxplots show the median, interquartile range, and range excluding outliers for each population. Study populations are arranged in descending order of median seroconversion rate assuming no seroreversion. *Ct* PCR measurements are identical to Figure 1 and are included for reference. For studies with only district-level estimates of PCR prevalence the mean is indicated with a circle rather than box plot. NA indicates that a study did not measure *Ct* infections with PCR.







Figure 4. Relationship between trachoma biomarkers in the presence and absence of recent mass drug administration (MDA). a Correlations between cluster PCR prevalence and seroprevalence overall and stratified by whether the study population had received MDA in the previous year. b Correlations between PCR prevalence and TF prevalence overall and stratified by whether the study population had received MDA in the previous year. In all panels, medians across clusters for each study population are represented by larger points with black outline. Each plot includes the identity line (dotted) and Pearson correlations at the cluster- and population-levels. 95% confidence intervals (CIs) are based on 1,000 bootstrapped samples, holding populations fixed and resampling clusters with replacement. Population-level values are included for Andabet, Dera, Woreta town, and Alefa, Ethiopia, but cluster-level values were not available for these populations. Abbreviations: ETH = Ethiopia; MWI = Malawi; NER = Niger; TZA = Tanzania.







Abbreviations: ETH = Ethiopia; NER = Niger; TZA = Tanzania; MWI = Malawi

Figure 6. Identification of clusters with *C. trachomatis* infection using seroprevalence.

(a) Sensitivity and specificity curves for identification of clusters with any *Ct* infections based on different seroprevalence thresholds among children 1-9 years old (n = 281 clusters, 99 clusters with PCR>0%). Vertical lines delineate sensitivity at 90% (solid line, 13.5% seroprevalence) and 80% (dotted line, 22.5% seroprevalence). Thin lines show sensitivity for each study population with cluster-level PCR measurements. Points at bottom of plot mark seroprevalence estimates for each study population. (b) Receiver operating characteristic (ROC) curves for all clusters (thick black line) and for each population (thin colored lines) with overall area-under-the-curve (AUC).